Survodutide Weight Loss: What the Clinical Trials Show

Survodutide produced an average of 16.6% body weight loss in its Phase 3 clinical trial, placing it ahead of the licensed dose of semaglutide and behind tirzepatide in the current landscape of injectable weight-loss medications.

*This article is for informational purposes only and does not constitute medical advice. Survodutide is not FDA-approved and is not available at Prescriva. Consult your healthcare provider about your treatment options.*

---

You may not have heard of survodutide yet. As of mid-2026, it sits just outside the public awareness that semaglutide and tirzepatide have earned. But if you follow obesity medicine, or if you are waiting for options beyond what is currently on the market, survodutide is a name worth knowing.

The drug targets weight loss through two separate biological pathways simultaneously. Its Phase 2 results were striking enough to launch a major Phase 3 program. And those Phase 3 topline results, released in April 2026, confirmed meaningful weight loss with a safety profile consistent with other drugs in its class.

This article explains the science, what the trial data actually shows, how survodutide stacks up against semaglutide and tirzepatide, and what a realistic timeline for availability looks like.

---

What Is Survodutide?

Survodutide (also known by its research designation BI 456906) is a once-weekly injectable medication developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is classified as a GLP-1 receptor and glucagon receptor dual agonist.

That classification describes something specific: survodutide activates two different hormone receptors at the same time. Most GLP-1 medications on the market today, including semaglutide and liraglutide, work primarily through the GLP-1 receptor. Tirzepatide adds a second target, the GIP receptor. Survodutide takes a different approach, pairing GLP-1 receptor activation with glucagon receptor activation.

Survodutide is being studied in people with overweight or obesity, both with and without type 2 diabetes, across a large Phase 3 program called SYNCHRONIZE. It has also been studied in metabolic-associated steatohepatitis (MASH, previously called NASH), a liver condition closely linked to obesity.

Survodutide is not FDA-approved. It is not available at Prescriva or any other telehealth or pharmacy provider.

---

How the Dual Mechanism Works

To understand why a glucagon receptor agonist would be added to a weight-loss drug, it helps to understand what glucagon normally does.

The GLP-1 Side

GLP-1 is released by the gut after eating. It acts on the hypothalamus (the brain region that controls appetite) to reduce hunger and slow gastric emptying. GLP-1 receptor agonists mimic this signal, which is why semaglutide and similar drugs reliably reduce caloric intake. You simply feel less hungry, and food passes through your stomach more slowly.

The Glucagon Side

Glucagon is usually thought of as the opposite of insulin: it raises blood sugar when levels drop too low. But glucagon has another function that is relevant to weight loss. Glucagon receptor activation increases energy expenditure. It raises resting metabolic rate by stimulating fat oxidation in the liver and generating heat (a process called thermogenesis). It also suppresses appetite through a separate signaling pathway.

When you combine GLP-1 receptor agonism with glucagon receptor agonism, you get two complementary effects: reduced calorie intake (from GLP-1) and increased calorie burning (from glucagon). The theory is that the combination produces greater weight loss than either target alone, without requiring higher doses of a single drug.

The glucagon signaling pathways that support this approach are well characterized in peer-reviewed literature (PMID: [41025406](https://pubmed.ncbi.nlm.nih.gov/41025406/)).

---

Clinical Trial Results

Phase 2: Proof of Concept

The Phase 2 dose-finding trial, published in *Lancet Diabetes and Endocrinology* in March 2024, enrolled adults with overweight or obesity who did not have type 2 diabetes (PMID: [38330987](https://pubmed.ncbi.nlm.nih.gov/38330987/)). Participants received once-weekly subcutaneous injections of survodutide at doses ranging from 0.6 mg to 4.8 mg, or placebo, over 46 weeks.

Key results at the highest studied dose (4.8 mg):

• Average body weight reduction: approximately 19%
• Participants who lost 5% or more of body weight: 83%
• Participants who lost 10% or more: 69%
• Participants who lost 15% or more: 55%
• Placebo group weight loss: approximately 2.8%

These numbers were strong enough to confirm dose-dependent weight loss and justify moving to Phase 3.

Phase 3: The SYNCHRONIZE Program

The Phase 3 program consists of two large trials. SYNCHRONIZE-1 enrolled adults with overweight or obesity without type 2 diabetes. SYNCHRONIZE-2 enrolled adults with overweight or obesity who also have type 2 diabetes. The trial design and baseline characteristics of SYNCHRONIZE-1 were published in early 2026 (PMID: [41187967](https://pubmed.ncbi.nlm.nih.gov/41187967/)).

Topline results from SYNCHRONIZE-1 were released in April 2026 and presented at the American Diabetes Association's 2026 Scientific Sessions:

• Average body weight reduction at 76 weeks: 16.6% (efficacy estimand)
• Placebo group: 3.2%
• Participants achieving 5% or more weight loss: 85.1%
• The reduction in body weight was driven predominantly by fat loss, with lean mass representing a small proportion of the total reduction

Survodutide met its co-primary endpoints, a meaningful bar for a drug in this category.

*Weight loss decisions work best when made with a healthcare provider who understands your full medical history.*

---

Survodutide vs Semaglutide vs Tirzepatide

Phase 3 results position survodutide in the middle of the current weight-loss drug landscape. The table below compares it to the two approved GLP-1-based medications and two other drugs in late-stage development.

A few important caveats apply when reading this table. These trials enrolled different populations, used different time points, and measured outcomes in slightly different ways. Direct head-to-head comparisons between drugs are not possible from this data alone. Survodutide's 16.6% Phase 3 result is modestly lower than its Phase 2 result of 19%, which is typical as drugs move from smaller dose-optimization studies to larger confirmatory trials.

For context on other emerging options, see our full breakdowns of [retatrutide](/resources/retatrutide-weight-loss) and [CagriSema](/resources/cagrisema-next-generation-glp1-amylin-weight-loss).

---

Side Effect Profile

Survodutide's side effects reported in clinical trials are consistent with other drugs in the GLP-1 class. The most common are gastrointestinal:

• Nausea (the most commonly reported side effect)
• Vomiting
• Diarrhea
• Constipation

These effects were typically dose-dependent and most pronounced during the dose-escalation phase. Nausea and vomiting tend to improve as the body adjusts to the medication. This pattern is familiar to anyone who has taken semaglutide or tirzepatide.

The glucagon receptor component raises a theoretical question about blood sugar. Glucagon raises blood glucose in normal physiology. In clinical trials, survodutide was studied primarily in people without type 2 diabetes, and the GLP-1 component appeared to offset any glucagon-mediated glucose elevation. However, how the drug behaves across diverse populations with different metabolic profiles is something regulators will examine closely during the approval process.

No unexpected safety signals emerged in Phase 2. The full Phase 3 safety dataset will be part of any New Drug Application review.

---

When Will Survodutide Be Available?

Boehringer Ingelheim and Zealand Pharma have not announced a formal NDA filing date as of June 2026. SYNCHRONIZE-2 (the trial in people with type 2 diabetes) is still completing its primary analysis. Regulators typically require both confirmatory trial datasets before approving a drug in this indication.

A realistic timeline, assuming SYNCHRONIZE-2 data are positive and the NDA is filed by late 2026 or early 2027, would place a potential FDA approval decision in 2027 or 2028. The FDA's standard review timeline is 12 months, with priority review reducing that to 6 months if granted.

Even if survodutide earns FDA approval, compounding it is unlikely to be a permitted pathway. Compounding is legally available for FDA-shortage-listed drugs. Semaglutide and tirzepatide were compounding-eligible in recent years because they appeared on the FDA shortage list. Survodutide is a new chemical entity without an established shortage designation.

---

What You Can Do Now

If you are managing your weight and want to start a medically supervised program today, rather than waiting for a drug that may be two or more years from availability, compounded semaglutide and tirzepatide are available through Prescriva now. Both have extensive Phase 3 trial evidence supporting their efficacy and safety profiles.

For more on how compounded semaglutide works and what distinguishes it from branded versions, see our guide: [What Is Compounded Semaglutide?](/resources/compounded-semaglutide-what-it-is)

Ready to explore your options? [Check your eligibility](/assessment) and connect with a Prescriva provider to discuss whether a GLP-1 program is right for you.

---

Sources

1. le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. *Lancet Diabetes Endocrinol.* 2024 Mar. PMID: [38330987](https://pubmed.ncbi.nlm.nih.gov/38330987/)

1. le Roux CW, et al. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1). *Diabetes Obes Metab.* 2026 Jan. PMID: [41187967](https://pubmed.ncbi.nlm.nih.gov/41187967/)

1. Wharton S, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). *Obesity (Silver Spring).* 2025 Jan. PMID: [39495965](https://pubmed.ncbi.nlm.nih.gov/39495965/)

1. Henderson SJ, et al. Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity. *Diabetes Obes Metab.* 2025 Dec. PMID: [41025406](https://pubmed.ncbi.nlm.nih.gov/41025406/)

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021 Mar 18. PMID: [33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med.* 2022 Jul 21. PMID: [35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)

---

*This article is for informational and educational purposes only. It does not constitute medical advice. Survodutide is an investigational drug that is not FDA-approved and is not available through Prescriva or any other healthcare provider. Prescriva offers compounded semaglutide and tirzepatide, which are not FDA-approved and are not the same as or equivalent to branded products. Individual results vary. Consult your healthcare provider before starting, stopping, or changing any medical treatment.*